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tudes in clinical practice. Data was collected on 1648 patients with T2DM receiving
at least one oral anti-diabetic with/without insulin and 141 specialists and 59 in-
ternal medicine physicians in 9 Chinese cities, through physician interviews, pa-
tient record forms, and self-completed questionnaires. RESULTS: Among the 200
physicians in the study, the most frequently reported concerns with starting insu-
lin were patient’s acceptance and ability to comply in the long-term (91.9% of
respondents), and the long timeneeded to train on injection techniques and dosing
(74.0%). Forty-three percent of physicians believe patients fear injections, but a
higher percentage of patients (55.3%) report not liking injections. Thirty-seven per-
cent of physicians believe social stigma is a barrier; only about 17.1% of insulin-
naive patients believe so. Among 474 insulin-naive patients, the most frequently
reported concern was that starting insulin would mean their diabetes is at an
advanced stage (67.5% of respondents). Physicians underestimate that concern,
with only 30% reporting that as a barrier. Almost half of insulin-naive patients
(45.1%) would consider insulin initiation as a personal failure to control their dia-
betes. Among 346 patients taking insulin, 60.1% reported feeling better and 55.7%
felt amore positive outlook since starting insulin; 59.8% thought insulinmade their
diabetes easier tomanage. CONCLUSIONS: Physicians in Chinamay over or under-
estimate patient perceived barriers to, and satisfaction with, insulin initiation.
Physician/patient education focused on perceived barriers to insulin initiation, and
patient/physician communication may facilitate the initiation of insulin in pa-
tientswith this progressive disease. Interventions to address system-level barriers,
e.g. time for training, are warranted.
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OBJECTIVES: To examine the effects on the health-related quality of life (HRQoL)
after starting insulin with, or switching to, biphasic insulin aspart 30 (BIAsp30) in
Chinese subjects with type 2 diabetes (T2DM) in the A1chieve study. METHODS:
The A1chieve study was a 24-week, prospective, non-interventional, observational
study conducted in routine clinical practices in 28 countries. In China, there were
8,578 T2DMpatients recruited from 131 hospitals into the BIAsp30 treatment group
(starting insulin with or switching to BIAsp30 at baseline based on physicians’
clinical judgments). HRQoLwas assessed at baseline and 24weeks by the validated
EQ-5D questionnaire (five dimensions and visual analogue scale (VAS)). Descriptive
statistics, paired t-test, and chi-square were conducted for the analyses. RESULTS:
Themean age of patients (SD) was 54.914.4 years. 57% were male. The reported
HRQoL as measured by VAS score (on a scale of 0-100) increased by 6.2 from 75.8 to
82.0 for the overall cohort (p0.001). For insulin naïve patients, starting insulin
with BIAsp30 was associated with a 6.1 increase in VAS score from 75.9 to 82.0
(p0.001). Similarly, for insulin experienced patients, switching to BIAsp30 was
associated with a 6.7 increase in VAS score from 75.3 to 82.0 (p0.001). For the
overall cohort in the five dimensions of EQ-5D, the percentage of patients reported
no problems in walking increased from 88.4% to 91.4% (p0.0001) after 24 weeks.
Similarly, the percentage of patients reported no pain or discomfort increased from
77.3% to 82.8% (p0.0001), reported not anxious or depressed increased from 74.2%
to 77.1% (p0.001). The percentage of patients reported no problems in self-care
and usual activity only slightly reduced (-0.2%, -0.5%, respectively) with no statis-
tical significance. CONCLUSIONS: Starting insulin with, or switching to, BIAsp30
were associated with significant HRQoL improvement in Chinese T2DM subjects of
the A1chieve study.
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Psychological distress often occurs in patients with diabetes, resulting in poorer
therapeutic outcomes. The Problem Areas in Diabetes (PAID) questionnaire covers
frequently reported diabetes related emotional problems. Utilizing PAID to identify
distressed diabetic patients would be beneficial. OBJECTIVES: PAID was originally
developed for the American population. Cross-cultural differences in health per-
ceptions are well documented; thus it is necessary to verify the validity and reli-
ability of PAID in Singapore. Design: Cross-sectional study. PARTICIPANTS: Pa-
tients with Type 2 diabetes, 21-65 years old, English-speaking, without obvious
cognitive impairment and visited the Diabetes Clinic at National University
Hospital.METHODS: Validity of the scale was evaluated by factor analysis, known
group (defined by socio-demographics and clinical variables), convergent/diver-
gent and concurrent validity. Reliability (internal consistency) was evaluated by
Cronbach’s alpha. RESULTS: Exploratory factor analysis revealed three factors. All
items loaded onto one factor (distress related problems). A few items loaded onto
multiple factors. PAID scores were significantly higher in patients with HbA1c 7.5%
(p0.02) and living in HDB 5-room or smaller flats (p0.01), supporting known
group validity. Other hypothesized known group differences were not observed.
PAID correlated significantly with Kessler10 (K10) and World Health Organization
Quality of Life (WHOQOL-BREF), thus demonstrating convergent and concurrent
validity. PAID correlatedweaklywithWHOQOL-BREF’s physical domain, thus dem-
onstrating divergent validity. Internal consistency was high (Cronbach’s
alpha0.96). CONCLUSIONS: PAID is a valid and reliable scale to evaluate diabetes-
related emotional distress in the Singaporean Type 2 diabetes population. Further
evidence on known group validity needs to be accumulated in future studies.
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OBJECTIVES: To examine the association between glycemic control and quality of
life (QoL) among patientswith type 2 diabetesmellitus (T2DM) in China.METHODS:
Data were obtained from a cross-sectional survey of T2DM patients in outpatient
settings from October to December 2011 in Beijing and Tianjin. Eligible patients
were 18 years, had a diagnosis of T2DM 1 year and received 1 year anti-
diabetic treatment at the time of survey. EQ-5D index score and visual analog scale
(VAS) score were calculated for all T2DM patients and compared between sub-
groups defined by fasting blood glucose control (FBG8 mmol/L) and 2-hour post-
prandial glucose control (2h-BG10mmol/L).Multivariate linear regressionmodels
were applied to assess the associations between glucose control and patient QoL,
adjusting for age, gender, BMI, weight gain, education and life style (including
smoking, drinking and exercise). RESULTS: A total of 500 patients with T2DMwere
included in the analysis with 54.6% female, mean age of 63.2 years and mean
disease duration of 11.5 years. Among them, 64.6% reported FBG8mmol/L and
45.6% reported 2h-BG10mmol/L based on the last test in the past 2 weeks. Mean
EQ-5D and VAS scores for all patients were 0.78 and 68.25, respectively. Compared
with patients without FBG control, patients with FBG control had significantly
higher EQ-5D (0.80 vs. 0.75, P0.005) and VAS scores (69.40 vs. 66.16, P0.017).
Similarly, patients with 2h-BG control had significantly higher scores than those
without 2h-BG control (0.82 vs. 0.75 for EQ-5D; 71.82 vs. 65.26 for VAS, both
P0.001). The regression analysis showed that 2h-BG control, but not FBG control,
was significantly associatedwith higher EQ-5D (P0.035) and VAS scores (P0.000).
Older age, less education, weight gain and less exercise were also significantly
associated with lower QoL. CONCLUSIONS: Better glycemic control at 2-hour post-
prandial is associated with improved QoL in patients with T2DM.
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OBJECTIVES: To assess efficacy and safety of tenofovir (TDF) as compared with
other nucleot(s)ide analogues (NAs) and peginterferon alpha 2a (PegIFN2a) for
naive chronic hepatitis B.METHODS: Comparison was based on randomized con-
trolled trials (RCTs) identified bymeans of systematic review, carried out according
to the Cochrane Collaboration guidelines. Studies met the inclusion criteria if they
directly compared at least two of the following interventions: TDF, PegIFN2a ETV,
ADV, LAMor placebo. Themost importantmedical databases (MEDLINE, CENTRAL,
EMBASE) were searched until February 2012. Two reviewers independently se-
lected trials, assessed their quality and extracted data. Mixed treatment compari-
son (MTC) was performed using WinBugs software. Subgroup analysis was per-
formed according hepatitis B antigen e status. RESULTS:We identified 20 relevant
studies. The results of MTC showed that in app. one year of follow up TDF signifi-
cantly increased the odds of HBV DNA clearance when compared with PegIFN2a
(OR 66.22 [5.98; 733.54]); ETV (OR 8.45 [1.12; 63.98]); ADV (OR 13.04 [3.62; 46.94])
and LAM (OR 41.72 [5.27; 330.54]). TDF was superior than PegIFN2a with respect
to ALT normalization (OR  3.07 [1.04; 9.09]) but did not differ significantly from
other NAs. Percentage of patients with any adverse events was significantly lower
in TDF group when compared with PegIFN2a (OR  0.19 [0.07; 0.48]), while no
differenceswere found between TDF and placebo aswell as other NAswith respect
to the safety profile. The rates of ALT flares were similar in all treatments arms. In
contrast to other NAs there were no resistance to TDF through five years.
CONCLUSIONS: TDF demonstrated the highest efficacy with respect to the reduc-
tion of viral load in treatment naïve patients with chronic HBV and maintained a
very good safety profile.
PIN2
ASSESSING THE DIAGNOSTIC PERFORMANCE OF HUMAN IMMUNODEFICIENCY
VIRUS TYPE 1 (HIV-1) TROPISM TESTING METHODS: A SYSTEMATIC REVIEW OF
GENOTYPIC SEQUENCING OF THE THIRD HYPERVARIABLE (V3) LOOP AND
ENHANCED-SENSITIVITY PHENOTYPIC ASSAY TECHNOLOGY
Needham MO, Paech D, Norris S, Campbell S
OptumInsight, Sydney, NSW, Australia
OBJECTIVES: To evaluate the relative diagnostic performance of genotypic se-
quencing and enhanced-sensitivity phenotypic testing methods for: i) identifying
the tropism of HIV-1 infected patients, and ii) predicting virological response to
CCR5-antagonist therapy. METHODS: A systematic review of the literature (via
EMBASE and Medline databases) initially identified 359 publications. Based on a
priori defined eligibility criteria, five studies were included in the final analysis.
RESULTS: Four of the five studies assessed the diagnostic performance of genotypic
testing in identifying viral tropism, with the enhanced-sensitivity Trofile assay
(ESTA) as the reference standard. Using the geno2pheno bioinformatic algorithm,
genotypic testing maintained a high concordance with ESTA (range: 70.6%-85.3%).
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